WSJ -- Valeant Pharmaceuticals International (VRX) said the Food and Drug Administration accepted for review its investigational drug to treat adult epilespy patients with partial-onset seizures. The drug, Retigabine, the company's best hope for a potential blockbuster, was shown to reduce seizure rates compared with a placebo in late-stage trials.
